Entry inhibitor

Entry inhibitors, also known as fusion inhibitors, are a class of antiviral drugs that prevent a virus from entering a cell, for example, by blocking a receptor. Entry inhibitors are used to treat conditions such as HIV, hepatitis D, and hepatitis B.

HIV entry

They are used in combination therapy for the treatment of HIV infection. This class of drugs interferes with the binding, fusion and entry of an HIV virion to a human cell. By blocking this step in HIV's replication cycle, such agents slow the progression from HIV infection to AIDS.

Proteins

There are several key proteins involved in the HIV entry process.^{[citation needed]}

CD4, a protein receptor found on the surface of helper T cells in the human immune system, also called CD4+ T cells
gp120, a protein on HIV surface that binds to the CD4 receptor
CCR5, a second receptor found on the surface of CD4+ cells and macrophages, called a chemokine co-receptor
CXCR4, another chemokine co-receptor found on CD4+ cells
gp41, an HIV protein, closely associated with gp120, that penetrates the cell membrane

Binding, fusion, entry sequence

HIV entry into a human cell requires the following steps in sequence.

The binding of HIV surface protein gp120 to the CD4 receptor
A conformational change in gp120, which both increases its affinity for a co-receptor and exposes gp41
The binding of gp120 to a co-receptor either CCR5 or CXCR4
The penetration of the cell membrane by gp41, which approximates the membrane of HIV and the T cell and promotes their fusion
The entry of the viral core into the cell

Entry inhibitors work by interfering with one aspect of this process.

Approved agents

Maraviroc binds to CCR5, preventing an interaction with gp120. It is also referred to as a "chemokine receptor antagonist" or a "CCR5 inhibitor."
Enfuvirtide binds to gp41 and interferes with its ability to approximate the two membranes. It is also referred to as a "fusion inhibitor."
Ibalizumab, a monoclonal antibody that binds to domain 2 of CD4 and interferes with post-attachment steps required for the entry of HIV-1 virus particles into host cells and prevents the viral transmission that occurs via cell-cell fusion.
Fostemsavir, an attachment inhibitor that interferes with the interaction of CD4 and gp120 by binding with gp120.
Bulevirtide (Hepcludex), is an entry inhibitor that blocks the NTCP receptor on liver cells, preventing Hepatitis B and D viruses from entering. It was granted full marketing authorization by the European Commission in 2023.

Investigational agents

Other agents are under investigation for their ability to interact with the proteins involved in HIV entry and the possibility that they may serve as entry inhibitors.

Leronlimab, a monoclonal antibody that binds CCR5
Plerixafor was being developed to interfere with interaction between HIV and CXCR4, but showed little useful antiviral activity in recent trials.
Epigallocatechin gallate, a substance found in green tea, appears to interact with gp120 as do several other theaflavins.
Vicriviroc, similar to maraviroc, is currently undergoing clinical trials for FDA approval.
Aplaviroc, an agent similar to maraviroc and vicriroc. Clinical trials were halted in 2005 over concerns about the drug's safety.
b12 is an antibody against HIV found in some long-term nonprogressors. It has been found to bind to gp120 at the exact region, or epitope, where gp120 binds to CD4. b12 seems to serve as a natural entry inhibitor in some individuals. It is hoped that further study of b12 may lead to an effective HIV vaccine.
Griffithsin, a substance derived from algae, appears to have entry inhibitor properties.
DCM205, is a small molecule based on L-chicoric acid, an integrase inhibitor. DCM205 has been reported to inactivate HIV-1 particles directly in vitro and is thought to act primarily as an entry inhibitor.
CD4 specific Designed Ankyrin Repeat Proteins (DARPins) potently block viral entry of diverse strains and are being developed and studied as potential microbicide candidates
A polyclonal caprine antibody is in phase II human clinical trials that targets, among others sites, the GP41 transmembrane glycoprotein. The trials are being conducted by Virionyx, a New Zealand Company.
VIR-576 is a synthesized peptide which binds to gp41, preventing fusion of the virus with a cell membrane.
ITX5061 for hepatitis C.

References

↑ "Hepcludex | European Medicines Agency (EMA)". www.ema.europa.eu. 2020-08-12. Retrieved 2026-03-10.
↑ Biswas P, Tambussi G, Lazzarin A (May 2007). "Access denied? The status of co-receptor inhibition to counter HIV entry". Expert Opinion on Pharmacotherapy. 8 (7): 923–33. doi:10.1517/14656566.8.7.923. PMID 17472538. S2CID 32675897.
↑ Xiao, Tianshu; Cai, Yongfei; Chen, Bing (2021). "HIV-1 entry and membrane fusion inhibitors". Viruses. 13 (5): 735. doi:10.3390/v13050735. PMC 8146413. PMID 33922579.
↑ Wilen, Craig B.; Tilton, John C.; Doms, Robert W. (2012). "HIV: cell binding and entry". Cold Spring Harb Perspect Med. 2 (8) a006866. doi:10.1101/cshperspect.a006866. PMC 3405824. PMID 22908191. Retrieved 2021-08-11.
↑ Pugach P, Ketas TJ, Michael E, Moore JP (August 2008). "Neutralizing antibody and anti-retroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitors". Virology. 377 (2): 401–7. doi:10.1016/j.virol.2008.04.032. PMC 2528836. PMID 18519143.
↑ "ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS" (PDF).
↑ Merck Manual.com Human Immunodeficiency Virus (HIV) Infection Table 4
↑ Williamson MP, McCormick TG, Nance CL, Shearer WT (December 2006). "Epigallocatechin gallate, the main polyphenol in green tea, binds to the T-cell receptor, CD4: Potential for HIV-1 therapy". The Journal of Allergy and Clinical Immunology. 118 (6): 1369–74. doi:10.1016/j.jaci.2006.08.016. PMID 17157668.
↑ Emau P, Tian B, O'keefe BR, Mori T, McMahon JB, Palmer KE, et al. (August 2007). "Griffithsin, a potent HIV entry inhibitor, is an excellent candidate for anti-HIV microbicide". Journal of Medical Primatology. 36 (4–5): 244–53. doi:10.1111/j.1600-0684.2007.00242.x. PMID 17669213. S2CID 22539115.
↑ Duong YT, Meadows DC, Srivastava IK, Gervay-Hague J, North TW (May 2007). "Direct inactivation of human immunodeficiency virus type 1 by a novel small-molecule entry inhibitor, DCM205". Antimicrobial Agents and Chemotherapy. 51 (5): 1780–6. doi:10.1128/AAC.01001-06. PMC 1855571. PMID 17307982.
↑ Schweizer A, Rusert P, Berlinger L, Ruprecht CR, Mann A, Corthésy S, et al. (July 2008). "CD4-specific designed ankyrin repeat proteins are novel potent HIV entry inhibitors with unique characteristics". PLOS Pathogens. 4 (7) e1000109. doi:10.1371/journal.ppat.1000109. PMC 2453315. PMID 18654624.
↑ "virionyx.com". Retrieved 2007-08-26.
↑ Sulkowski MS, Kang M, Matining R, Wyles D, Johnson VA, Morse GD, et al. (March 2014). "Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b study". The Journal of Infectious Diseases. 209 (5): 658–67. doi:10.1093/infdis/jit503. PMC 3923538. PMID 24041792.

External links

Fusion Inhibitor Resource Center
HIV+Fusion+Inhibitors at the U.S. National Library of Medicine Medical Subject Headings (MeSH)

[1] "Hepcludex | European Medicines Agency (EMA)". www.ema.europa.eu. 2020-08-12. Retrieved 2026-03-10.

[pmid17472538-2] Biswas P, Tambussi G, Lazzarin A (May 2007). "Access denied? The status of co-receptor inhibition to counter HIV entry". Expert Opinion on Pharmacotherapy. 8 (7): 923–33. doi:10.1517/14656566.8.7.923. PMID 17472538. S2CID 32675897.

[3] Xiao, Tianshu; Cai, Yongfei; Chen, Bing (2021). "HIV-1 entry and membrane fusion inhibitors". Viruses. 13 (5): 735. doi:10.3390/v13050735. PMC 8146413. PMID 33922579.

[4] Wilen, Craig B.; Tilton, John C.; Doms, Robert W. (2012). "HIV: cell binding and entry". Cold Spring Harb Perspect Med. 2 (8) a006866. doi:10.1101/cshperspect.a006866. PMC 3405824. PMID 22908191. Retrieved 2021-08-11.

[pmid18519143-5] Pugach P, Ketas TJ, Michael E, Moore JP (August 2008). "Neutralizing antibody and anti-retroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitors". Virology. 377 (2): 401–7. doi:10.1016/j.virol.2008.04.032. PMC 2528836. PMID 18519143.

[6] "ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS" (PDF).

[mm-7] Merck Manual.com Human Immunodeficiency Virus (HIV) Infection Table 4

[8] Williamson MP, McCormick TG, Nance CL, Shearer WT (December 2006). "Epigallocatechin gallate, the main polyphenol in green tea, binds to the T-cell receptor, CD4: Potential for HIV-1 therapy". The Journal of Allergy and Clinical Immunology. 118 (6): 1369–74. doi:10.1016/j.jaci.2006.08.016. PMID 17157668.

[9] Emau P, Tian B, O'keefe BR, Mori T, McMahon JB, Palmer KE, et al. (August 2007). "Griffithsin, a potent HIV entry inhibitor, is an excellent candidate for anti-HIV microbicide". Journal of Medical Primatology. 36 (4–5): 244–53. doi:10.1111/j.1600-0684.2007.00242.x. PMID 17669213. S2CID 22539115.

[10] Duong YT, Meadows DC, Srivastava IK, Gervay-Hague J, North TW (May 2007). "Direct inactivation of human immunodeficiency virus type 1 by a novel small-molecule entry inhibitor, DCM205". Antimicrobial Agents and Chemotherapy. 51 (5): 1780–6. doi:10.1128/AAC.01001-06. PMC 1855571. PMID 17307982.

[11] Schweizer A, Rusert P, Berlinger L, Ruprecht CR, Mann A, Corthésy S, et al. (July 2008). "CD4-specific designed ankyrin repeat proteins are novel potent HIV entry inhibitors with unique characteristics". PLOS Pathogens. 4 (7) e1000109. doi:10.1371/journal.ppat.1000109. PMC 2453315. PMID 18654624.

[12] "virionyx.com". Retrieved 2007-08-26.

[13] Sulkowski MS, Kang M, Matining R, Wyles D, Johnson VA, Morse GD, et al. (March 2014). "Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b study". The Journal of Infectious Diseases. 209 (5): 658–67. doi:10.1093/infdis/jit503. PMC 3923538. PMID 24041792.